Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform, LillyDirect.
The drugmaker said in a Dec. 1 news release the price cut is part of a broader effort to reduce out-of-pocket costs and expand access for people with obesity. The 5-milligram dose is now priced at $399 per month, while all other approved doses, 7.5 to 15 milligrams, cost $449 per month through Lilly’s Self-Pay Journey Program. These prices are lower than the drug’s regular range of $599 to $1,049 per month.
The announcement comes amid intensifying competition in the GLP-1 market. On Nov. 17, Novo Nordisk said it would offer new patients its GLP-1 drugs Ozempic and Wegovy at $199 per month for the first two months of treatment. After that, the monthly price will rise to $349, with TrumpRx set to sell the drugs for $350.
Lilly and Novo Nordisk also reached a federal pricing agreement in November to extend Medicare and Medicaid coverage for GLP-1s beginning in 2026. Under the deal, Zepbound, Mounjaro, Ozempic and Wegovy will be priced at $245 per month for Medicare, with a $50 copay for patients. The companies also agreed to apply most-favored-nation pricing to future obesity and diabetes drugs and to reinvest billions of dollars in U.S. manufacturing.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.